Perspectives in medicinal chemistry
| LEADER | cam a22 4 4500 | ||
|---|---|---|---|
| 001 | 294677615 | ||
| 003 | CHVBK | ||
| 005 | 20200922104932.0 | ||
| 008 | 131020s1993 sz a b||| 101 0 eng| | ||
| 010 | |a 93015334 | ||
| 016 | 7 | |a 930315367 |2 DE-101 | |
| 016 | 7 | |a 9305713 |2 DNLM | |
| 020 | |a 3-906390-04-7 |q (VCHA | ||
| 020 | |a 978-3-906390-04-8 |q (VCHA | ||
| 020 | |a 3-527-28486-9 |q (VCH | ||
| 020 | |a 978-3-527-28486-3 |q (VCH | ||
| 020 | |z 1-56081-252-4 |q (VCH | ||
| 020 | |a 978-1-56081-252-4 | ||
| 020 | |a 1-56081-252-4 | ||
| 035 | |a (IDSBB)006508840 | ||
| 035 | |a (SNL)991002345369703976 | ||
| 035 | |a (NEBIS)000700140 | ||
| 035 | |a (OCoLC)27854747 |z (OCoLC)28850849 |z (OCoLC)29308523 |z (OCoLC)232534459 | ||
| 035 | |a (Sz)52193-41snl_51 | ||
| 035 | |a (Sz)vtls000052193 | ||
| 035 | |a (Sz)000052193 | ||
| 040 | |a DNLM/DLC |b ger |c DLC |d NLM |d UBA |d OCL |d BAKER |d NLGGC |d BTCTA |d YDXCP |d HEBIS |d DEBBG |d OCLCQ |d BDX |d GBVCP |d OCLCO |d OCLCF |d OCLCQ |d OCLCO |d OCL |d OCLCO |d OCLCQ |d OCLCO |d SzZuIDS BS/BE A228 |e rda | ||
| 050 | 0 | 0 | |a RS401 |b .P47 1993 |
| 060 | 0 | 0 | |a QV 744 |b P467 1993 |
| 082 | 0 | 0 | |a 615/.19 |2 20 |
| 084 | |a 44.33 |2 bcl | ||
| 084 | |a 44.38 |2 bcl | ||
| 084 | |a VS 5000 |2 rvk | ||
| 084 | |a VS 5408 |2 rvk | ||
| 084 | |a YB 1700 |2 rvk | ||
| 084 | |a YB 1705 |2 rvk | ||
| 111 | 2 | |a International Symposium on Medicinal Chemistry |n (12 |d 1992 |c Basel) |0 (DE-588)2141575-4 | |
| 245 | 1 | 0 | |a Perspectives in medicinal chemistry |c Editors: Bernard Testa [und andere] |
| 264 | 1 | |a Basel |b VHCA |c [1993] |a Weinheim |a New York |b VCH | |
| 300 | |a xii, 644 Seiten |b Illustrationen |c 25 cm | ||
| 500 | |a Proceedings of the 12th International Symposium on Medicinal Chemistry | ||
| 504 | |a Includes bibliographical references and index | ||
| 650 | 2 | |a Chemistry, Pharmaceutical |0 (DNLM)D002626 | |
| 650 | 2 | |a Drug Design |0 (DNLM)D015195 | |
| 650 | 2 | |a Drug Therapy |0 (DNLM)D004358 | |
| 650 | 2 | |a Pharmacology |0 (DNLM)D010600 | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast | |
| 650 | 7 | |a Medische chemie |2 gtt | |
| 650 | 7 | |a Farmacochemie |2 gtt | |
| 650 | 7 | |a Geneesmiddelen |2 gtt | |
| 650 | 7 | |a Quimica farmaceutica |2 larpcal | |
| 650 | 7 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |2 gnd | |
| 650 | 7 | |a Klinische Chemie |0 (DE-588)4135255-5 |2 gnd | |
| 650 | 0 | |a Pharmaceutical chemistry |x Congresses | |
| 650 | 7 | |a Klinische Chemie |2 idszbz | |
| 650 | 7 | |a ARZNEIMITTELREZEPTOREN (PHARMAKOLOGIE) |x ger |0 (ETHUDK)000046931 |2 ethudk | |
| 650 | 7 | |a ARZNEIMITTELVERGIFTUNG + GIFTIGE ARZNEIMITTEL |x ger |0 (ETHUDK)000026901 |2 ethudk | |
| 650 | 7 | |a ENZYMINHIBITION + ENZYMINAKTIVIERUNG (BIOCHEMIE) |x ger |0 (ETHUDK)000022020 |2 ethudk | |
| 650 | 7 | |a IONENKANÄLE (MEMBRANBIOLOGIE) |x ger |0 (ETHUDK)000040413 |2 ethudk | |
| 650 | 7 | |a MEDIZINISCHE BIOCHEMIE + MEDIZINISCHE MOLEKULARBIOLOGIE |x ger |0 (ETHUDK)000021734 |2 ethudk | |
| 650 | 7 | |a PHARMAKODYNAMIK + ARZNEIMITTELWIRKUNG (PHARMAKOLOGIE) |x ger |0 (ETHUDK)000026617 |2 ethudk | |
| 650 | 7 | |a PRODRUGS (ARZNEIFORMEN) |x ger |0 (ETHUDK)000026804 |2 ethudk | |
| 650 | 7 | |a PROTEINE, POLYPEPTIDE, ENZYME, ENZYMINHIBITOREN, PEPTIDE (PHARMAZIE) |x ger |0 (ETHUDK)000026783 |2 ethudk | |
| 650 | 7 | |a STRUKTUR-WIRKUNG BEZIEHUNG, CHEMISCHE EINFLÜSSE AUF ARZNEIMITTELWIRKUNG (PHARMAKOLOGIE) |x ger |0 (ETHUDK)000026619 |2 ethudk | |
| 650 | 7 | |a ZIELGERICHTETE ARZNEIMITTEL (PHARMAKOLOGIE) |x ger |0 (ETHUDK)000039312 |2 ethudk | |
| 653 | |a Chemistry, Pharmaceutical |a congresses | ||
| 653 | |a Drug Design |a congresses | ||
| 653 | |a Drug Therapy |a congresses | ||
| 653 | |a Pharmaceutical chemistry |a Congresses | ||
| 653 | |a Pharmacology |a congresses | ||
| 655 | 2 | |a Congress |0 (DNLM)D016423 | |
| 655 | 7 | |a Conference papers and proceedings |2 fast | |
| 655 | 7 | |a Kongress |z Basel |y 1992 |2 gnd | |
| 655 | 7 | |a Konferenzschrift |z Basel |y 1992/09 |2 gnd-content | |
| 655 | 7 | |a Aufsatzsammlung |2 idszbz | |
| 691 | 7 | |a 615.10:54 |2 snl local | |
| 691 | 7 | |a 615.0(061.3) |2 snl local | |
| 691 | 7 | |a sb |b 1995/17 |c 18 |2 snl-sb | |
| 691 | 7 | |B u |a MEDIZINISCHE BIOCHEMIE + MEDIZINISCHE MOLEKULARBIOLOGIE |z ger |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a PROTEINE, POLYPEPTIDE, ENZYME, ENZYMINHIBITOREN, PEPTIDE (PHARMAZIE) |z ger |u 615.355 |2 nebis E1 | |
| 691 | 7 | |B u |a ENZYMINHIBITION + ENZYMINAKTIVIERUNG (BIOCHEMIE) |z ger |u 577.151.042.2 |2 nebis E1 | |
| 691 | 7 | |B u |a ARZNEIMITTELREZEPTOREN (PHARMAKOLOGIE) |z ger |u 615.015.44*2 |2 nebis E1 | |
| 691 | 7 | |B u |a STRUKTUR-WIRKUNG BEZIEHUNG, CHEMISCHE EINFLÜSSE AUF ARZNEIMITTELWIRKUNG (PHARMAKOLOGIE) |z ger |u 615.015.11 |2 nebis E1 | |
| 691 | 7 | |B u |a ZIELGERICHTETE ARZNEIMITTEL (PHARMAKOLOGIE) |z ger |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a PRODRUGS (ARZNEIFORMEN) |z ger |u 615.014,9.015.4.014.43 |2 nebis E1 | |
| 691 | 7 | |B u |a PHARMAKODYNAMIK + ARZNEIMITTELWIRKUNG (PHARMAKOLOGIE) |z ger |u 615.015.1/.8 |2 nebis E1 | |
| 691 | 7 | |B u |a IONENKANÄLE (MEMBRANBIOLOGIE) |z ger |u 577.352.465,2 |2 nebis E1 | |
| 691 | 7 | |B u |a ARZNEIMITTELVERGIFTUNG + GIFTIGE ARZNEIMITTEL |z ger |u 615.9.099.061 |2 nebis E1 | |
| 691 | 7 | |B u |a BIOCHIMIE MÉDICALE + BIOLOGIE MOLÉCULAIRE MÉDICALE |z fre |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a MEDICAL BIOCHEMISTRY + MEDICAL MOLECULAR BIOLOGY |z eng |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a PROTÉINES, POLYPEPTIDES, ENZYMES, INHIBITEURS ENZYMATIQUES, PEPTIDES (PHARMACIE) |z fre |u 615.355 |2 nebis E1 | |
| 691 | 7 | |B u |a PROTEINS, POLYPEPTIDES, ENZYMES, ENZYME INHIBITORS, PEPTIDES (PHARMACY) |z eng |u 615.355 |2 nebis E1 | |
| 691 | 7 | |B u |a INHIBITION, INACTIVATION ENZYMATIQUE (BIOCHIMIE) |z fre |u 577.151.042.2 |2 nebis E1 | |
| 691 | 7 | |B u |a ENZYME INHIBITION + ENZYME INACTIVATION (BIOCHEMISTRY) |z eng |u 577.151.042.2 |2 nebis E1 | |
| 691 | 7 | |B u |a DRUG RECEPTORS (PHARMACOLOGY) |z eng |u 615.015.44*2 |2 nebis E1 | |
| 691 | 7 | |B u |a RÉCEPTEURS DE MÉDICAMENTS (PHARMACOLOGIE) |z fre |u 615.015.44*2 |2 nebis E1 | |
| 691 | 7 | |B u |a RELATION ENTRE STRUCTURE ET EFFETS DES MÉDICAMENTS (PHARMACOLOGIE) |z fre |u 615.015.11 |2 nebis E1 | |
| 691 | 7 | |B u |a STRUCTURE-ACTIVITY RELATIONSHIP + CHEMICAL INFLUENCE ON DRUG ACTION (PHARMACOLOGY) |z eng |u 615.015.11 |2 nebis E1 | |
| 691 | 7 | |B u |a MÉDICAMENTS CIBLÉS (PHARMACOLOGIE) |z fre |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a TARGETED DRUGS (PHARMACOLOGY) |z eng |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a PRODROGUES (FORMES DE MÉDICAMENTS) |z fre |u 615.014,9.015.4.014.43 |2 nebis E1 | |
| 691 | 7 | |B u |a PRODRUGS (PHARMACEUTICALS) |z eng |u 615.014,9.015.4.014.43 |2 nebis E1 | |
| 691 | 7 | |B u |a PHARMACODYNAMICS + DRUG ACTION (PHARMACOLOGY) |z eng |u 615.015.1/.8 |2 nebis E1 | |
| 691 | 7 | |B u |a PHARMACODYNAMIQUE + ACTION DES MÉDICAMENTS (PHARMACOLOGIE) |z fre |u 615.015.1/.8 |2 nebis E1 | |
| 691 | 7 | |B u |a CANAUX À IONS (BIOLOGIE DES MEMBRANES) |z fre |u 577.352.465,2 |2 nebis E1 | |
| 691 | 7 | |B u |a ION CHANNELS (MEMBRANE BIOLOGY) |z eng |u 577.352.465,2 |2 nebis E1 | |
| 691 | 7 | |B u |a INTOXICATION PAR MÉDICAMENTS + MÉDICAMENTS TOXIQUES |z fre |u 615.9.099.061 |2 nebis E1 | |
| 691 | 7 | |B u |a PHARMACOTOXICOLOGY + TOXIC MEDICAMENTS |z eng |u 615.9.099.061 |2 nebis E1 | |
| 700 | 1 | |a Testa |D Bernard |e Herausgeber |4 edt | |
| 856 | 4 | 1 | |3 Table of contents |u http://www.gbv.de/dms/bowker/toc/9783527284863.pdf |
| 898 | |a BK020800 |b XK020000 |c XK020000 | ||
| 912 | 7 | |a ch |2 SzZuIDS BS/BE | |
| 913 | |a Kongress = Congrès |b 1992/09 |c Basel | ||
| 949 | |B SNL |F NB001 |b NB001 |j N 219458 |c NB10010 | ||
| 949 | |B IDSBB |F A228 |b A228 |c FH |j CHE BIO 12 |x Geschenk/Nachlass 06.06.2016 | ||
| 950 | |B IDSBB |P 111 |E 2- |a International Symposium on Medicinal Chemistry |n (12 |d 1992 |c Basel) |0 (DE-588)2141575-4 | ||
| 950 | |B IDSBB |P 700 |E 1- |a Testa |D Bernard |e Herausgeber |4 edt | ||
| 950 | |B IDSBB |P 856 |E 41 |3 Table of contents |u http://www.gbv.de/dms/bowker/toc/9783527284863.pdf | ||
| 950 | |B SNL |P 700 |E 1- |a Testa |D Bernard | ||
| 950 | |B SNL |P 711 |E 2- |a International Symposium on Medicinal Chemistry |n (12 |d 1992 |c Basel) | ||
| 950 | |B SNL |P 711 |E 2- |a Kongress |d (1992 |c Basel, BS) | ||
| 950 | |B NEBIS |P 700 |E 1- |a Testa |D Bernard | ||
| 950 | |B NEBIS |P 711 |E 2- |a International Symposium on Medicinal Chemistry |0 (DE-588)1091906149 | ||